Patients stratified into subgroups based on different CD9 expression levels in the tumors also segregated known prognostic markers such as age at diagnosis (≤ or > 18 months), and INSS tumor stages 3 or 4 versus stages 1, 2 or 4S. The gene discussed is CD9; the disease is neoplasm.